Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lipikar Urea is a topical dermatological product, primarily a body lotion or cream, developed and manufactured by La Roche-Posay. Its key active ingredient is urea, typically at a concentration of 10%, though other concentrations like 30% exist. It is formulated with additional moisturizing and soothing components such as shea butter and allantoin. The product is designed to intensely hydrate, exfoliate, soften, and smooth dry, rough, flaky, and bumpy skin. It works by improving the skin's moisture barrier function and providing long-lasting hydration. While often marketed as a skincare product, its active ingredient, urea, has well-established therapeutic properties, including humectant, keratolytic, and skin barrier-enhancing effects, making it relevant for various dermatological conditions. It is being investigated in clinical trials for its use in conjunction with treatments for actinic keratoses to improve tolerability and efficacy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Lipikar Urea.